The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
Takeaways: Novo Nordisk is defending branded Ozempic’s market share by narrowing the price gap with generic semaglutide for uninsured Canadians. That should help reduce switching to lower-cost a...
Takeaways: Ontario’s reimbursement of Braftovi is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
Takeaways: IHEEZO gives Apotex a differentiated, in‑clinic anesthetic that strengthens its positioning with Canadian ophthalmologists and complements its anti‑inflammatory an...
Takeaways MedExpress is adding another low-cost telehealth channel for generic semaglutide in Canada, which should increase competition among virtual clinics and make GLP‑1 access even easier fo...
The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
The digital health sector has experienced a dramatic rise over the past decade, fueled by venture capital, pandemic driven demand, and a wave of innovation promising to transform healthcare delivery. ...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
